The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome
暂无分享,去创建一个
[1] J. Craig,et al. Corticosteroid therapy for nephrotic syndrome in children. , 2020, The Cochrane database of systematic reviews.
[2] J. Craig,et al. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. , 2016, The Cochrane database of systematic reviews.
[3] A. Adeyemo,et al. HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic Syndrome. , 2015, Journal of the American Society of Nephrology : JASN.
[4] S. Engelmann,et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. , 2015, Journal of the American Society of Nephrology : JASN.
[5] B. C. Kwan,et al. Long-term outcome of biopsy-proven minimal change nephropathy in Chinese adults. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] A. Anarat,et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[7] A. Edefonti,et al. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. , 2015, Journal of the American Society of Nephrology : JASN.
[8] E. Daugas,et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] R. Mori,et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial , 2014, The Lancet.
[10] V. Jha,et al. Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[11] E. Ota,et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment , 2014, Kidney international.
[12] J. Wetzels,et al. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[13] A. Bruchfeld,et al. Rituximab for minimal change disease in adults: long-term follow-up. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] M. Rudnicki,et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. , 2014, Journal of the American Society of Nephrology : JASN.
[15] Taixiang Wu,et al. Lipid-lowering agents for nephrotic syndrome. , 2013, The Cochrane database of systematic reviews.
[16] J. Radhakrishnan,et al. The treatment of minimal change disease in adults. , 2013, Journal of the American Society of Nephrology : JASN.
[17] M. Rudnicki,et al. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases , 2013, Wiener klinische Wochenschrift.
[18] J. Radhakrishnan,et al. Impact of the National Institutes of Health Focal Segmental Glomerulosclerosis (NIH FSGS) clinical trial on the treatment of steroid-resistant FSGS. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[19] K. Dahan,et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. , 2013, Kidney international.
[20] Ľ. Podracká,et al. [Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis)]. , 2013, Vnitrni lekarstvi.
[21] N. Chen,et al. Tacrolimus versus Cyclophosphamide in Steroid-Dependent or Steroid-Resistant Focal Segmental Glomerulosclerosis: A Randomized Controlled Trial , 2013, American Journal of Nephrology.
[22] A. Sinha,et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. , 2012, Kidney international.
[23] D. Cattran,et al. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. , 2012, Kidney international.
[24] A. Fornoni,et al. Podocyte Foot Process Effacement in Postreperfusion Allograft Biopsies Correlates With Early Recurrence of Proteinuria in Focal Segmental Glomerulosclerosis , 2012, Transplantation.
[25] Jai Radhakrishnan,et al. Notice , 2012, Kidney International Supplements.
[26] S. Palmer,et al. Trial quality in nephrology: how are we measuring up? , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] B. Tazón-Vega,et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[28] D. Leaf,et al. Glomerular disease: why is there a dearth of high quality clinical trials? , 2010, Kidney international.
[29] C. Antignac,et al. Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations , 2010, Pediatric Nephrology.
[30] J. Egido,et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[31] J. G. van den Berg,et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. , 2008, Kidney international.
[32] V. D’Agati. The spectrum of focal segmental glomerulosclerosis: new insights , 2008, Current opinion in nephrology and hypertension.
[33] J. Nagy,et al. [Focal segmental glomerulosclerosis]. , 2008, Orvosi hetilap.
[34] V. D’Agati,et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[35] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[36] J. Scholey,et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. , 2005, Journal of the American Society of Nephrology : JASN.
[37] E. Lewis,et al. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. , 2004, Journal of the American Society of Nephrology : JASN.
[38] L. Moreland,et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate , 2004, Annals of the rheumatic diseases.
[39] Jonathan C Craig,et al. The number, quality, and coverage of randomized controlled trials in nephrology. , 2004, Journal of the American Society of Nephrology : JASN.
[40] G. Filler,et al. Is there really an increase in non-minimal change nephrotic syndrome in children? , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[41] T. Chan,et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[42] R. Portman,et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. , 1999, Kidney international.
[43] J. Grimshaw,et al. Potential benefits, limitations, and harms of clinical guidelines , 1999, BMJ.
[44] R. Doherty. Long term follow up , 1999, BMJ.
[45] D. Cattran,et al. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[46] M. Haas,et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[47] S. Mak,et al. Long-term outcome of adult-onset minimal-change nephropathy , 1996 .
[48] M. Schwartz,et al. The racial prevalence of glomerular lesions in nephrotic adults. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[49] M. Schwartz,et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[50] E. Lewis,et al. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[51] C. Ponticelli,et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. , 1991, Clinical nephrology.
[52] J. Cameron,et al. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. , 1986, Kidney international.
[53] C. Chantler,et al. The long-term prognosis of patients with focal segmental glomerulosclerosis. , 1978, Clinical nephrology.
[54] M. Rotondi,et al. Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression. , 2015, Journal of the American Society of Nephrology : JASN.
[55] A. Sinha,et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. , 2015, Kidney international.
[56] A. Sinha,et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[57] W. Hop,et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. , 2013, Journal of the American Society of Nephrology : JASN.
[58] M. Brittberg,et al. A Long-term Follow-up , 2013 .
[59] D. Molony,et al. Randomized controlled trials in nephrology: state of the evidence and critiquing the evidence. , 2012, Advances in chronic kidney disease.
[60] T. Mochizuki,et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. , 2012, Internal medicine.
[61] E. Morales,et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[62] Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. , 1981, Kidney international.